[{"orgOrder":0,"company":"Locate Bio","sponsor":"Mercia Ventures","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"UNITED KINGDOM","productType":"Protein","year":"2024","type":"Funding","leadProduct":"rhBMP-2","moa":"Activin receptor type-1 | Bone morphogenetic protein receptor type-1A | Activin receptor type-2B | Bone morphogenetic protein receptor type-2 | Bone morphogenetic protein receptor type-1B | Activin receptor type-2A","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Preclinical","graph3":"Locate Bio","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Orthopedics","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Locate Bio \/ Mercia Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Locate Bio \/ Mercia Ventures"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ligandrol","moa":"Androgen Receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viking Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SWITZERLAND","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"LNA043","moa":"Angiopoietin-related protein 3 (ANGPTL3)","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BRAZIL","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eurofarma Laboratorios S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Undisclosed"},{"orgOrder":0,"company":"Tetec AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"GERMANY","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Matrix-Associated Autologous Chondrocytes","moa":"Autologous chondrocytes","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Tetec AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Tetec AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tetec AG \/ Undisclosed"},{"orgOrder":0,"company":"Omeros","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"OMS103HP-S","moa":"Bacterial cell membrane","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Omeros \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Undisclosed"},{"orgOrder":0,"company":"Mercy Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Cefazolin","moa":"Bacterial penicillin-binding protein","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Mercy Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mercy Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mercy Health \/ Undisclosed"},{"orgOrder":0,"company":"Stayble Therapeutics","sponsor":"Cromsource | Antaros Medical | Viedoc","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lactic Acid","moa":"Bifunctional protein PutA; NimA-related protein","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Stayble Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stayble Therapeutics \/ Cromsource | Antaros Medical | Viedoc","highestDevelopmentStatusID":"6","companyTruncated":"Stayble Therapeutics \/ Cromsource | Antaros Medical | Viedoc"},{"orgOrder":0,"company":"Amorphical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"ISRAEL","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Calcium Carbonate","moa":"Calcium","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Amorphical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amorphical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Amorphical \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CANADA","productType":"Controlled Substance","year":"2018","type":"Inapplicable","leadProduct":"Cannabinol","moa":"cannabinol derivatives","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II\/ Phase III","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unity Health Toronto \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Unity Health Toronto \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"AUSTRALIA","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"MSB-CAR001","moa":"CD19","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Isto Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Allogenic Juvenile Chondrocytes","moa":"Chondrocyte","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Isto Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isto Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Isto Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Seikagaku","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"JAPAN","productType":"Enzyme","year":"2013","type":"Inapplicable","leadProduct":"Condoliase","moa":"Chondroitin-6-sulfate | Hyaluronic acid","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Seikagaku","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seikagaku \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seikagaku \/ Undisclosed"},{"orgOrder":0,"company":"Seikagaku","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"JAPAN","productType":"Enzyme","year":"2015","type":"Inapplicable","leadProduct":"Condoliase","moa":"Chondroitin-6-sulfate | Hyaluronic acid","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Seikagaku","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seikagaku \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seikagaku \/ Undisclosed"},{"orgOrder":0,"company":"Seikagaku","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"JAPAN","productType":"Enzyme","year":"2018","type":"Inapplicable","leadProduct":"SI-6603","moa":"Chondroitin-6-sulfate | Hyaluronic acid","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Seikagaku","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seikagaku \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seikagaku \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"BAY1213790","moa":"Coagulation factor XI","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Milvexian","moa":"Coagulation factor XI","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Milvexian","moa":"Coagulation factor XI","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"eXIthera Pharmaceutical","sponsor":"IDT CMAX Clinical Trials | Syneos Health | CPR Pharma Services","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"EP-7041","moa":"Coagulation factor XI (F11)","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"eXIthera Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"eXIthera Pharmaceutical \/ IDT CMAX Clinical Trials | Syneos Health | CPR Pharma Services","highestDevelopmentStatusID":"6","companyTruncated":"eXIthera Pharmaceutical \/ IDT CMAX Clinical Trials | Syneos Health | CPR Pharma Services"},{"orgOrder":0,"company":"Anika Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Anika Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Anika Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anika Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Europainclinics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Europainclinics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Europainclinics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Europainclinics \/ Undisclosed"},{"orgOrder":0,"company":"ZetrOZ, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Diclofenac","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"ZetrOZ, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Patch","sponsorNew":"ZetrOZ, Inc. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ZetrOZ, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Strategic Science & Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Strategic Science & Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Cream","sponsorNew":"Strategic Science & Technologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Strategic Science & Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Corporacion Parc Tauli","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SPAIN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dexketoprofen Trometamol","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Corporacion Parc Tauli","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corporacion Parc Tauli \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Corporacion Parc Tauli \/ Undisclosed"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"IRELAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Diclofenac Epolamine","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Patch","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Diclofenac Potassium","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Diclofenac Sodium","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Diclofenac Sodium","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Teikoku Seiyaku","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Esflurbiprofen","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Teikoku Seiyaku","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Teikoku Seiyaku \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teikoku Seiyaku \/ Undisclosed"},{"orgOrder":0,"company":"Teikoku Seiyaku","sponsor":"CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services | Clinsearch GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Esflurbiprofen","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Teikoku Seiyaku","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teikoku Seiyaku \/ CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services | Clinsearch GmbH","highestDevelopmentStatusID":"10","companyTruncated":"Teikoku Seiyaku \/ CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services | Clinsearch GmbH"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Gel","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Rundo International Pharmaceutical Research & Development","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Indomethacin","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Rundo International Pharmaceutical Research & Development","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Rundo International Pharmaceutical Research & Development"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Naproxen","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"MedRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Etodolac","moa":"Cyclooxygenase-2","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"MedRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Patch","sponsorNew":"MedRx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MedRx \/ Undisclosed"},{"orgOrder":0,"company":"MedRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Etodolac","moa":"Cyclooxygenase-2","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"MedRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Patch","sponsorNew":"MedRx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MedRx \/ Undisclosed"},{"orgOrder":0,"company":"Nantes University Hospital","sponsor":"Radiometer Medical ApS","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Oxygen","moa":"Cytochrome c oxidase subunit 1; NADPH oxidase 1","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Nantes University Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nantes University Hospital \/ Radiometer Medical ApS","highestDevelopmentStatusID":"10","companyTruncated":"Nantes University Hospital \/ Radiometer Medical ApS"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Rexlemestrocel-L","moa":"estrogens","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Rexlemestrocel-L","moa":"estrogens","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mesoblast \/ Quintiles Inc","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Quintiles Inc"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Calcium Phosphate","moa":"Extracellular calcium-sensing receptor; Calreticulin; Calcium and integrin-binding protein 1; Programmed cell death protein 6; Sorcin; Calcineurin B homologous protein 1; SPARC; Calnexin; Fibrillin-2; Protein S100-B; Calsequestrin-2; Regucalcin; Peflin; Protein S100-A6; Translationally-controlled tumor protein; Calcium and integrin-binding family member 2; Protein S100-A13; Calsequestrin-1; Nucleobindin-1; Nucleobindin-2; Fibrillin-3; Grancalcin; Calcium-dependent secretion activator 1; Calmodulin-2; Calmodulin-3; Protein S100-A16; Calretinin; Calcyphosin; Calcium-dependent secretion activator 2; Calreticulin-3; Neurexin-1; Neuronal calcium sensor 1; Calmodulin","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Carmell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Carmell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Calcium Phosphate","moa":"||Extracellular calcium-sensing receptor; Calreticulin; Calcium and integrin-binding protein 1; Programmed cell death protein 6; Sorcin; Calcineurin B homologous protein 1; SPARC; Calnexin; Fibrillin-2; Protein S100-B; Calsequestrin-2; Regucalcin; Peflin; Protein S100-A6; Translationally-controlled tumor protein; Calcium and integrin-binding family member 2; Protein S100-A13; Calsequestrin-1; Nucleobindin-1; Nucleobindin-2; Fibrillin-3; Grancalcin; Calcium-dependent secretion activator 1; Calmodulin-2; Calmodulin-3; Protein S100-A16; Calretinin; Calcyphosin; Calcium-dependent secretion activator 2; Calreticulin-3; Neurexin-1; Neuronal calcium sensor 1; Calmodulin","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Carmell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Carmell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TeaRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tearxaban","moa":"factor Xa","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"TeaRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TeaRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TeaRx \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Clermont-Ferrand","sponsor":"INSERM CIC 501","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"FRANCE","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Disodium Pamidronate Pentahydrate","moa":"Farnesyl diphosphate synthase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"University Hospital, Clermont-Ferrand","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Clermont-Ferrand \/ INSERM CIC 501","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital, Clermont-Ferrand \/ INSERM CIC 501"},{"orgOrder":0,"company":"Seoul National University Bundang Hospital","sponsor":"JW Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SOUTH KOREA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Seoul National University Bundang Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Bundang Hospital \/ JW Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Bundang Hospital \/ JW Pharmaceutical"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"SAR442501","moa":"Fibroblast growth factor receptor 3 (FGFR3)","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"SAR442501","moa":"Fibroblast growth factor receptor 3 (FGFR3)","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Butylated Hydroxyanisole","moa":"Free radical","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Carmell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Carmell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Butylated Hydroxyanisole","moa":"Free radical","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Carmell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Carmell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartiva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Betamethasone","moa":"Glucocorticoid receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Cartiva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartiva \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cartiva \/ Undisclosed"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unity Health Toronto \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Unity Health Toronto \/ Undisclosed"},{"orgOrder":0,"company":"Robert Wood Johnson Barnabas Health","sponsor":"Brielle Orthopedics | University Orthopedics Associates","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II\/ Phase III","graph3":"Robert Wood Johnson Barnabas Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Robert Wood Johnson Barnabas Health \/ Brielle Orthopedics | University Orthopedics Associates","highestDevelopmentStatusID":"9","companyTruncated":"Robert Wood Johnson Barnabas Health \/ Brielle Orthopedics | University Orthopedics Associates"},{"orgOrder":0,"company":"Wake Forest University Health Sciences","sponsor":"Carolinas Trauma Network Research Group | Charlotte, Houston, Milwaukee Prehospital Emergency Research Nodal Center-CHaMP-ERNC","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Wake Forest University Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wake Forest University Health Sciences \/ Carolinas Trauma Network Research Group | Charlotte, Houston, Milwaukee Prehospital Emergency Research Nodal Center-CHaMP-ERNC","highestDevelopmentStatusID":"8","companyTruncated":"Wake Forest University Health Sciences \/ Carolinas Trauma Network Research Group | Charlotte, Houston, Milwaukee Prehospital Emergency Research Nodal Center-CHaMP-ERNC"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Controlled Substance","year":"2017","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Terumo BCT, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Platelet Rich Plasma","moa":"Growth factor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Colorado, Denver \/ Terumo BCT, Inc","highestDevelopmentStatusID":"1","companyTruncated":"University of Colorado, Denver \/ Terumo BCT, Inc"},{"orgOrder":0,"company":"University of Wisconsin, Madison","sponsor":"DePuy Synthes","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Platelet Rich Plasma","moa":"Growth factor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"University of Wisconsin, Madison","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Wisconsin, Madison \/ DePuy Synthes","highestDevelopmentStatusID":"8","companyTruncated":"University of Wisconsin, Madison \/ DePuy Synthes"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Platelet Rich Plasma","moa":"Growth factor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Regenexx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Platelet Rich Plasma","moa":"Growth factor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Regenexx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regenexx \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Regenexx \/ Undisclosed"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"GERMANY","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Sprifermin","moa":"growth factors: fibroblast growth factors","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Sprifermin","moa":"growth factors: fibroblast growth factors","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"EMD Serono \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EMD Serono \/ Undisclosed"},{"orgOrder":0,"company":"Histogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"HST-003","moa":"Hyaline cartilage","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"IND Enabling","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Histogen \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Histogen \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Daprodustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"XT-150","moa":"IL-10R","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Xalud Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Solution","sponsorNew":"Xalud Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xalud Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revalesio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"RNS60","moa":"IntraCellular signaling","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Revalesio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revalesio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revalesio \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"GERMANY","productType":"Controlled Substance","year":"2011","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Ashibio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Andecaliximab","moa":"Matrix metalloproteinase 9","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Ashibio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ashibio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ashibio \/ Undisclosed"},{"orgOrder":0,"company":"Anterogen Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SOUTH KOREA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Allo-Asc","moa":"Mesenchymal stem cell","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Anterogen Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anterogen Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Anterogen Co \/ Undisclosed"},{"orgOrder":0,"company":"Causeway Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tenomir","moa":"miRNA","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Causeway Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Causeway Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Causeway Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Causeway Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tenomir","moa":"miRNA","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Causeway Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Causeway Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Causeway Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Ambit Biosciences | Kern Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Ambit Biosciences | Kern Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"Mayo Clinic \/ Ambit Biosciences | Kern Medical Center"},{"orgOrder":0,"company":"International Clinical Research Institute","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"International Clinical Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"International Clinical Research Institute \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"International Clinical Research Institute \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"University of Tennessee Graduate School of Medicine","sponsor":"Attralus","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"124-I Evuzamitide","moa":"MUC1","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"University of Tennessee Graduate School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Tennessee Graduate School of Medicine \/ Attralus","highestDevelopmentStatusID":"8","companyTruncated":"University of Tennessee Graduate School of Medicine \/ Attralus"},{"orgOrder":0,"company":"Universitaire Ziekenhuizen KU Leuven","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Rocuronium Bromide","moa":"Muscle-type nicotinic acetylcholine receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Universitaire Ziekenhuizen KU Leuven","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universitaire Ziekenhuizen KU Leuven \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Universitaire Ziekenhuizen KU Leuven \/ Merck & Co"},{"orgOrder":0,"company":"IWK Health Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"IWK Health Centre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IWK Health Centre \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IWK Health Centre \/ Undisclosed"},{"orgOrder":0,"company":"Sanford Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Sanford Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanford Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanford Health \/ Undisclosed"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Physician Services Incorporated | Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CANADA","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Teriparatide","moa":"Parathyroid hormone receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"University Health Network, Toronto \/ Physician Services Incorporated | Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"University Health Network, Toronto \/ Physician Services Incorporated | Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Teriparatide","moa":"Parathyroid hormone receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Teriparatide","moa":"Parathyroid hormone receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Hvidovre University Hospital","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"DENMARK","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Parathyroid Hormone (1-84)","moa":"Parathyroid hormone-1 receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Hvidovre University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hvidovre University Hospital \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Hvidovre University Hospital \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Kuros Biosciences","sponsor":"Avania | Kuros Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TGplPTH1-34","moa":"Parathyroid hormone-1 receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Kuros Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kuros Biosciences \/ Avania | Kuros Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Kuros Biosciences \/ Avania | Kuros Biosciences"},{"orgOrder":0,"company":"University of Manitoba","sponsor":"Health Sciences Centre Winnipeg","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CANADA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"University of Manitoba","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Manitoba \/ Health Sciences Centre Winnipeg","highestDevelopmentStatusID":"11","companyTruncated":"University of Manitoba \/ Health Sciences Centre Winnipeg"},{"orgOrder":0,"company":"Indiana Hand to Shoulder Center","sponsor":"CTM Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cefotiam","moa":"Peptidoglycan synthase FtsI; Penicillin-binding protein 1A","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Indiana Hand to Shoulder Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indiana Hand to Shoulder Center \/ CTM Biomedical","highestDevelopmentStatusID":"8","companyTruncated":"Indiana Hand to Shoulder Center \/ CTM Biomedical"},{"orgOrder":0,"company":"Basque Health Service","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SPAIN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Basque Health Service","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basque Health Service \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Basque Health Service \/ Undisclosed"},{"orgOrder":0,"company":"UConn Health","sponsor":"Orthopedic Research and Education Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"UConn Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"UConn Health \/ Orthopedic Research and Education Foundation","highestDevelopmentStatusID":"11","companyTruncated":"UConn Health \/ Orthopedic Research and Education Foundation"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"Exela Pharma Sciences, LLC.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Exela Pharma Sciences, LLC.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Exela Pharma Sciences, LLC. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Exela Pharma Sciences, LLC. \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Campbell Clinic","sponsor":"Duke University | The University of Pittsburgh School of Medicine | Endeavor Health | University of Cincinnati | Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Campbell Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Campbell Clinic \/ Duke University | The University of Pittsburgh School of Medicine | Endeavor Health | University of Cincinnati | Washington University School of Medicine","highestDevelopmentStatusID":"11","companyTruncated":"Campbell Clinic \/ Duke University | The University of Pittsburgh School of Medicine | Endeavor Health | University of Cincinnati | Washington University School of Medicine"},{"orgOrder":0,"company":"Inspire Health Medical Group","sponsor":"Arbi Nazarian, MD","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Inspire Health Medical Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inspire Health Medical Group \/ Arbi Nazarian, MD","highestDevelopmentStatusID":"11","companyTruncated":"Inspire Health Medical Group \/ Arbi Nazarian, MD"},{"orgOrder":0,"company":"Yale University","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Yale University \/ Genentech"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Romosozumab","moa":"Sclerostin","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"University College Cork","sponsor":"Health Service Executive","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"IRELAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"University College Cork","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University College Cork \/ Health Service Executive","highestDevelopmentStatusID":"1","companyTruncated":"University College Cork \/ Health Service Executive"},{"orgOrder":0,"company":"Kendall Healthcare Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Kendall Healthcare Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kendall Healthcare Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Kendall Healthcare Group \/ Undisclosed"},{"orgOrder":0,"company":"Injury Care Medical Center","sponsor":"Nuvo Research Inc","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Injury Care Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Injury Care Medical Center \/ Nuvo Research Inc","highestDevelopmentStatusID":"8","companyTruncated":"Injury Care Medical Center \/ Nuvo Research Inc"},{"orgOrder":0,"company":"ZARS Pharma Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"ZARS Pharma Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Patch","sponsorNew":"ZARS Pharma Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ZARS Pharma Inc. \/ Undisclosed"},{"orgOrder":0,"company":"ZARS Pharma Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"ZARS Pharma Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Patch","sponsorNew":"ZARS Pharma Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ZARS Pharma Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Prisma Health-Upstate","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Mepivacaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Prisma Health-Upstate","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prisma Health-Upstate \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Prisma Health-Upstate \/ Undisclosed"},{"orgOrder":0,"company":"Hopital de l'Enfant-Jesus","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Hopital de l'Enfant-Jesus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hopital de l'Enfant-Jesus \/ Sanofi","highestDevelopmentStatusID":"1","companyTruncated":"Hopital de l'Enfant-Jesus \/ Sanofi"},{"orgOrder":0,"company":"University of South Florida","sponsor":"Pacira BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II\/ Phase III","graph3":"University of South Florida","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of South Florida \/ Pacira BioSciences","highestDevelopmentStatusID":"9","companyTruncated":"University of South Florida \/ Pacira BioSciences"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"NETHERLANDS","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ ZonMw","highestDevelopmentStatusID":"11","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ ZonMw"},{"orgOrder":0,"company":"Trinity Health of New England","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Trinity Health of New England","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trinity Health of New England \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Trinity Health of New England \/ Undisclosed"},{"orgOrder":0,"company":"Broward Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Broward Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Broward Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Broward Health \/ Undisclosed"},{"orgOrder":0,"company":"Northern Light Mercy Hospital","sponsor":"MaineHealth","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Northern Light Mercy Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Northern Light Mercy Hospital \/ MaineHealth","highestDevelopmentStatusID":"11","companyTruncated":"Northern Light Mercy Hospital \/ MaineHealth"},{"orgOrder":0,"company":"North American Institute for Continuing Medical Education","sponsor":"New York School of Regional Anesthesia | Pacira BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"North American Institute for Continuing Medical Education","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"North American Institute for Continuing Medical Education \/ New York School of Regional Anesthesia | Pacira BioSciences","highestDevelopmentStatusID":"1","companyTruncated":"North American Institute for Continuing Medical Education \/ New York School of Regional Anesthesia | Pacira BioSciences"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"TriHealth","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"TriHealth","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection, Solution, Extended Release","sponsorNew":"TriHealth \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TriHealth \/ Undisclosed"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Arboretum Ventures","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series C Financing","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0.059999999999999998,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Arboretum Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Arboretum Ventures"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Maruishi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Maruishi Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Maruishi Pharmaceutical"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Heron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Cristalia Produtos Quimicos Farma. Ltda","sponsor":"Santa Casa de S\u00e3o Paulo | Servi\u00e7o Social da Ind\u00fastria do Papel","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BRAZIL","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Cristalia Produtos Quimicos Farma. Ltda","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cristalia Produtos Quimicos Farma. Ltda \/ Santa Casa de S\u00e3o Paulo | Servi\u00e7o Social da Ind\u00fastria do Papel","highestDevelopmentStatusID":"10","companyTruncated":"Cristalia Produtos Quimicos Farma. Ltda \/ Santa Casa de S\u00e3o Paulo | Servi\u00e7o Social da Ind\u00fastria do Papel"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CANADA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"Arthritis Innovation Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Arthritis Innovation Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arthritis Innovation Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arthritis Innovation Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Sanford Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Sanford Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanford Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanford Health \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Sclnow Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CHINA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Sclnow Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sclnow Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sclnow Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Ensol BioSciences","sponsor":"Spine BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"SB-01","moa":"TGF-beta-1","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Ensol BioSciences","amount2":0.16,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0.16,"dosageForm":"Undisclosed","sponsorNew":"Ensol BioSciences \/ Spine BioPharma","highestDevelopmentStatusID":"10","companyTruncated":"Ensol BioSciences \/ Spine BioPharma"},{"orgOrder":0,"company":"Spine BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SB-01","moa":"TGF-beta-1","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Spine BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spine BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spine BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"University of California, Irvine","sponsor":"Gencor","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"University of California, Irvine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Irvine \/ Gencor","highestDevelopmentStatusID":"8","companyTruncated":"University of California, Irvine \/ Gencor"},{"orgOrder":0,"company":"Kolon TissueGene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"TG-C","moa":"Transforming growth factor beta 1 (TGFB1)","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Kolon TissueGene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kolon TissueGene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kolon TissueGene \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Amgen Inc"},{"orgOrder":0,"company":"Dove Medical Press","sponsor":"The Affiliated Hospital of Qingdao University | Nakhia Impex","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Dove Medical Press","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Solution","sponsorNew":"Dove Medical Press \/ The Affiliated Hospital of Qingdao University | Nakhia Impex","highestDevelopmentStatusID":"1","companyTruncated":"Dove Medical Press \/ The Affiliated Hospital of Qingdao University | Nakhia Impex"},{"orgOrder":0,"company":"Virtua Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"5CC Vivigen","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Virtua Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virtua Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Virtua Health \/ Undisclosed"},{"orgOrder":0,"company":"Angitia Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"AGA111","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Angitia Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Angitia Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Angitia Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Angitia Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AGA111","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Angitia Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Angitia Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Angitia Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Angitia Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"AGA111","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Angitia Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Angitia Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Angitia Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Allob","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Icon Plc"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2020","type":"Acquisition","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Bone Therapeutics \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"ABO Securities","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2022","type":"Financing","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ ABO Securities","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ ABO Securities"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Pregene","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2022","type":"Termination","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ Pregene","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Pregene"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2021","type":"Private Placement","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medsenic","sponsor":"Bone Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2022","type":"Acquisition","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Medsenic","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Medsenic \/ Bone Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Medsenic \/ Bone Therapeutics"},{"orgOrder":0,"company":"BioSenic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioSenic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Undisclosed"},{"orgOrder":0,"company":"BioSenic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioSenic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Undisclosed"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"ABO Securities","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2022","type":"Agreement","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ ABO Securities","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ ABO Securities"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2020","type":"Acquisition","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Bone Therapeutics \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"Allogeneic Bone-Forming Cell Therapy","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Allogeneic Bone-Forming Cell Therapy","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bone Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Red de Terapia Celular","sponsor":"Citospin | University of Valladolid","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Allogeneic Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Red de Terapia Celular","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Red de Terapia Celular \/ Citospin | University of Valladolid","highestDevelopmentStatusID":"7","companyTruncated":"Red de Terapia Celular \/ Citospin | University of Valladolid"},{"orgOrder":0,"company":"Medipost","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Medipost","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medipost \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medipost \/ Undisclosed"},{"orgOrder":0,"company":"Hyundai Bioland","sponsor":"Medipost","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Hyundai Bioland","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hyundai Bioland \/ Medipost","highestDevelopmentStatusID":"10","companyTruncated":"Hyundai Bioland \/ Medipost"},{"orgOrder":0,"company":"AnGes","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"AMG0103","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnGes \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AnGes \/ Undisclosed"},{"orgOrder":0,"company":"Red de Terapia Celular","sponsor":"Instituto Murciano de Investigaci\u00f3n Biosanitaria Virgen de la Arrixaca | Fundacion para la Formacion e Investigacion Sanitarias | Hospital Universitario Virgen de la Arrixaca | Spanish National Health System | Public Health Service, Murcia","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Autologous Bone Marrow Stem Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Red de Terapia Celular","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Red de Terapia Celular \/ Instituto Murciano de Investigaci\u00f3n Biosanitaria Virgen de la Arrixaca | Fundacion para la Formacion e Investigacion Sanitarias | Hospital Universitario Virgen de la Arrixaca | Spanish National Health System | Public Health Service, Murcia","highestDevelopmentStatusID":"6","companyTruncated":"Red de Terapia Celular \/ Instituto Murciano de Investigaci\u00f3n Biosanitaria Virgen de la Arrixaca | Fundacion para la Formacion e Investigacion Sanitarias | Hospital Universitario Virgen de la Arrixaca | Spanish National Health System | Public Health Service, Murcia"},{"orgOrder":0,"company":"Histogenics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2010","type":"Inapplicable","leadProduct":"Autologous Cartilagenous Tissue","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Histogenics Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Histogenics Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Histogenics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"OrthoCellix","sponsor":"Carisma Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Merger","leadProduct":"Autologous Cartilagenous Tissue","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"OrthoCellix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"OrthoCellix \/ Carisma Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"OrthoCellix \/ Carisma Therapeutics"},{"orgOrder":0,"company":"BonusBio Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Autologous Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"BonusBio Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BonusBio Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BonusBio Group \/ Undisclosed"},{"orgOrder":0,"company":"Tetec AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Autologous Chondrocyte","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Tetec AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Tetec AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tetec AG \/ Undisclosed"},{"orgOrder":0,"company":"The University of Western Australia","sponsor":"Arthrex","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"AUSTRALIA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Autologous Conditioned Plasma","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"The University of Western Australia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"The University of Western Australia \/ Arthrex","highestDevelopmentStatusID":"10","companyTruncated":"The University of Western Australia \/ Arthrex"},{"orgOrder":0,"company":"Biosolution","sponsor":"Kyunghee University Medical Center | Gangnam Severance Hospital | Severance Hospital | GCP unit, Copenhagen University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Autologous Chondrocyte","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biosolution","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Biosolution \/ Kyunghee University Medical Center | Gangnam Severance Hospital | Severance Hospital | GCP unit, Copenhagen University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Biosolution \/ Kyunghee University Medical Center | Gangnam Severance Hospital | Severance Hospital | GCP unit, Copenhagen University Hospital"},{"orgOrder":0,"company":"Biosolution","sponsor":"Kyung Hee University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Autologous Chondrocyte","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biosolution","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Biosolution \/ Kyung Hee University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Biosolution \/ Kyung Hee University Hospital"},{"orgOrder":0,"company":"Kasiak Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"INDIA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Autologous Human Platelet Lysate","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Kasiak Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kasiak Research \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kasiak Research \/ Undisclosed"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"Autologous Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"GALZU INSTITUTE OF RESEARCH, TEACHING, SCIENCE AND APPLIED TECHNOLOGY, Brazil","sponsor":"University of Liege | Bone Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BRAZIL","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Autologous Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"GALZU INSTITUTE OF RESEARCH, TEACHING, SCIENCE AND APPLIED TECHNOLOGY, Brazil","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"GALZU INSTITUTE OF RESEARCH, TEACHING, SCIENCE AND APPLIED TECHNOLOGY, Brazil \/ University of Liege | Bone Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"GALZU INSTITUTE OF RESEARCH, TEACHING, SCIENCE AND APPLIED TECHNOLOGY, Brazil \/ University of Liege | Bone Therapeutics"},{"orgOrder":0,"company":"KLSMC Stem Cells","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Autologous Peripheral Blood Stem Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"KLSMC Stem Cells","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"KLSMC Stem Cells \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"KLSMC Stem Cells \/ Undisclosed"},{"orgOrder":0,"company":"Seton Healthcare Family","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"BIO4","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Seton Healthcare Family","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seton Healthcare Family \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Seton Healthcare Family \/ Undisclosed"},{"orgOrder":0,"company":"Regenexx","sponsor":"Biorestorative Therapies","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Agreement","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Regenexx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regenexx \/ Biorestorative Therapies","highestDevelopmentStatusID":"8","companyTruncated":"Regenexx \/ Biorestorative Therapies"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Northwell Health Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Agreement","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Northwell Health Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Northwell Health Cancer Institute"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Public Offering","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Titan Partners Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biorestorative Therapies \/ Undisclosed"},{"orgOrder":0,"company":"ScinnoHub Pharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BT-14143","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"ScinnoHub Pharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"ScinnoHub Pharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ScinnoHub Pharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Technological Centre of Nutrition and Health, Spain","sponsor":"Hospital Universitari Sant Joan de Reus | University Rovira i Virgili","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2017","type":"Inapplicable","leadProduct":"B-Turmactive","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Technological Centre of Nutrition and Health, Spain","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Technological Centre of Nutrition and Health, Spain \/ Hospital Universitari Sant Joan de Reus | University Rovira i Virgili","highestDevelopmentStatusID":"1","companyTruncated":"Technological Centre of Nutrition and Health, Spain \/ Hospital Universitari Sant Joan de Reus | University Rovira i Virgili"},{"orgOrder":0,"company":"DiscGenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Discogenic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"DiscGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DiscGenics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"DiscGenics \/ Undisclosed"},{"orgOrder":0,"company":"DiscGenics","sponsor":"CTI Clinical Trial and Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Discogenic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"DiscGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DiscGenics \/ CTI Clinical Trial and Consulting","highestDevelopmentStatusID":"7","companyTruncated":"DiscGenics \/ CTI Clinical Trial and Consulting"},{"orgOrder":0,"company":"Orthox","sponsor":"Parkwalk","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Series A Financing","leadProduct":"Fibroin","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Orthox","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0.01,"dosageForm":"Implant","sponsorNew":"Orthox \/ Parkwalk","highestDevelopmentStatusID":"1","companyTruncated":"Orthox \/ Parkwalk"},{"orgOrder":0,"company":"Laboratorios Ordesa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SPAIN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Fontactiv Superprotein","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Laboratorios Ordesa","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Ordesa \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Laboratorios Ordesa \/ Undisclosed"},{"orgOrder":0,"company":"Hospital Clinic of Barcelona","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SPAIN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"HMB","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Hospital Clinic of Barcelona","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Clinic of Barcelona \/ Abbott Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Hospital Clinic of Barcelona \/ Abbott Laboratories"},{"orgOrder":0,"company":"Metabolic Technologies","sponsor":"Iowa State University","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2015","type":"Inapplicable","leadProduct":"HMB","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Metabolic Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metabolic Technologies \/ Iowa State University","highestDevelopmentStatusID":"1","companyTruncated":"Metabolic Technologies \/ Iowa State University"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HR18034","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Histogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"HST 004","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Preclinical","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Histogen \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Histogen \/ Undisclosed"},{"orgOrder":0,"company":"Histogen","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HST003","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Histogen \/ US Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Histogen \/ US Department of Defense"},{"orgOrder":0,"company":"Shanghai East Hospital","sponsor":"Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CHINA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Human Amniotic Epithelial Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Shanghai East Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai East Hospital \/ Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai East Hospital \/ Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China"},{"orgOrder":0,"company":"Bioinova","sponsor":"University Hospital Motol","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CZECH REPUBLIC","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Human Autologous Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Bioinova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Bioinova \/ University Hospital Motol","highestDevelopmentStatusID":"7","companyTruncated":"Bioinova \/ University Hospital Motol"},{"orgOrder":0,"company":"Green Cross Wellbeing","sponsor":"Chung-Ang University Hosptial, Chung-Ang University College of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Human Placenta Hydrolysate","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Green Cross Wellbeing","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Green Cross Wellbeing \/ Chung-Ang University Hosptial, Chung-Ang University College of Medicine","highestDevelopmentStatusID":"1","companyTruncated":"Green Cross Wellbeing \/ Chung-Ang University Hosptial, Chung-Ang University College of Medicine"},{"orgOrder":0,"company":"Sclnow Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CHINA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Human Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Sclnow Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sclnow Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sclnow Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"IPACK Block","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"KN060","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alphamab Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alphamab Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"JAPAN","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"KTP-001","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Teijin Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teijin Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Teijin Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Children's Hospital of Philadelphia","sponsor":"Bracco | Pediatric Orthopaedic Society of North America","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Sulfur Hexafluoride","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Children's Hospital of Philadelphia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital of Philadelphia \/ Bracco | Pediatric Orthopaedic Society of North America","highestDevelopmentStatusID":"6","companyTruncated":"Children's Hospital of Philadelphia \/ Bracco | Pediatric Orthopaedic Society of North America"},{"orgOrder":0,"company":"Odense University Hospital","sponsor":"Independent Research Fund Denmark","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Macrogol 3350","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Odense University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Odense University Hospital \/ Independent Research Fund Denmark","highestDevelopmentStatusID":"11","companyTruncated":"Odense University Hospital \/ Independent Research Fund Denmark"},{"orgOrder":0,"company":"Banc de Sang i Teixits","sponsor":"TFS Trial Form Support | Ministry of Health and Social Services, Spain | Ministry of Science and Innovation, Spain","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Banc de Sang i Teixits","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Banc de Sang i Teixits \/ TFS Trial Form Support | Ministry of Health and Social Services, Spain | Ministry of Science and Innovation, Spain","highestDevelopmentStatusID":"7","companyTruncated":"Banc de Sang i Teixits \/ TFS Trial Form Support | Ministry of Health and Social Services, Spain | Ministry of Science and Innovation, Spain"},{"orgOrder":0,"company":"Pluri","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Mesenchymal-Like Adherent Stromal Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pluri \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pluri \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"AUSTRALIA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"MPCs","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Alternativa International S.A","sponsor":"Artialis","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Myostim","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Alternativa International S.A","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alternativa International S.A \/ Artialis","highestDevelopmentStatusID":"1","companyTruncated":"Alternativa International S.A \/ Artialis"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"NOV004","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"IND Enabling","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quince Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Quince Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NutraHeal","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Nutraheal","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"NutraHeal","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NutraHeal \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NutraHeal \/ Undisclosed"},{"orgOrder":0,"company":"University of Maryland, Baltimore","sponsor":"National Institute on Aging | Arcadia University | UConn Health | Dartmouth-Hitchcock Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"Nutrition","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"University of Maryland, Baltimore","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Maryland, Baltimore \/ National Institute on Aging | Arcadia University | UConn Health | Dartmouth-Hitchcock Medical Center","highestDevelopmentStatusID":"1","companyTruncated":"University of Maryland, Baltimore \/ National Institute on Aging | Arcadia University | UConn Health | Dartmouth-Hitchcock Medical Center"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2012","type":"Inapplicable","leadProduct":"Nutritional Supplement","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"NVD-003","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novadip Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"NVD-003","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novadip Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"PrimeVigilance Ltd | Data Investigation Company Europe","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NVDX3","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Novadip Biosciences \/ PrimeVigilance Ltd | Data Investigation Company Europe","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Biosciences \/ PrimeVigilance Ltd | Data Investigation Company Europe"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"PrimeVigilance Ltd | Data Investigation Company Europe","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NVDX3","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Novadip Biosciences \/ PrimeVigilance Ltd | Data Investigation Company Europe","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Biosciences \/ PrimeVigilance Ltd | Data Investigation Company Europe"},{"orgOrder":0,"company":"DiscGenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Rebonuputemcel","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"DiscGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"DiscGenics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"DiscGenics \/ Undisclosed"},{"orgOrder":0,"company":"DiscGenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Rebonuputemcel","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"DiscGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"DiscGenics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"DiscGenics \/ Undisclosed"},{"orgOrder":0,"company":"DiscGenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Rebonuputemcel","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"DiscGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"DiscGenics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"DiscGenics \/ Undisclosed"},{"orgOrder":0,"company":"DePuy Spine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Recombinant Human GDF-5","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"DePuy Spine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"DePuy Spine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DePuy Spine \/ Undisclosed"},{"orgOrder":0,"company":"BioMimetic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Recombinant Human PDGF-BB","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"BioMimetic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioMimetic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioMimetic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seton Healthcare Family","sponsor":"Celling Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Solum Iv","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Seton Healthcare Family","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seton Healthcare Family \/ Celling Biosciences","highestDevelopmentStatusID":"11","companyTruncated":"Seton Healthcare Family \/ Celling Biosciences"},{"orgOrder":0,"company":"Cell Therapy Ltd.","sponsor":"George Papanicolaou Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Tendoncel","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Cell Therapy Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Gel","sponsorNew":"Cell Therapy Ltd. \/ George Papanicolaou Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Cell Therapy Ltd. \/ George Papanicolaou Hospital"},{"orgOrder":0,"company":"Heel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Traumeel","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Heel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Gel","sponsorNew":"Heel \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Heel \/ Undisclosed"},{"orgOrder":0,"company":"Heel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Traumeel","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Heel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Heel \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Heel \/ Undisclosed"},{"orgOrder":0,"company":"BioTissue Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TTAX03","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"BioTissue Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioTissue Holdings \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioTissue Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Qianfoshan Hospital","sponsor":"Shandong Qilu Stem Cells Engineering Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Umbilical Cord Blood Mononuclear Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Qianfoshan Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qianfoshan Hospital \/ Shandong Qilu Stem Cells Engineering Co., Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Qianfoshan Hospital \/ Shandong Qilu Stem Cells Engineering Co., Ltd."},{"orgOrder":0,"company":"William Beaumont Hospitals","sponsor":"DePuy Synthes","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Vivigen Cellular Bone Matrix","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"William Beaumont Hospitals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"William Beaumont Hospitals \/ DePuy Synthes","highestDevelopmentStatusID":"1","companyTruncated":"William Beaumont Hospitals \/ DePuy Synthes"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Xr Recovery Supplement","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Biosplice","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Lorecivivint","moa":"vinca alkaloids; WNT (wingless-type mouse mammary tumor virus) pathway inhibitors","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biosplice \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biosplice \/ Undisclosed"},{"orgOrder":0,"company":"Medical University of Bialystok","sponsor":"Lomza State University of Applied Sciences | International Science & Health Foundation | American Medical Holdings Inc","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"POLAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2019","type":"Inapplicable","leadProduct":"Vitamin D","moa":"Vitamin D receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Medical University of Bialystok","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical University of Bialystok \/ Lomza State University of Applied Sciences | International Science & Health Foundation | American Medical Holdings Inc","highestDevelopmentStatusID":"1","companyTruncated":"Medical University of Bialystok \/ Lomza State University of Applied Sciences | International Science & Health Foundation | American Medical Holdings Inc"},{"orgOrder":0,"company":"McMaster University","sponsor":"Canadian Institutes of Health Research | McMaster Surgical Associates | Hamilton Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Vitamin D","moa":"Vitamin D receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"McMaster University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McMaster University \/ Canadian Institutes of Health Research | McMaster Surgical Associates | Hamilton Health Sciences","highestDevelopmentStatusID":"10","companyTruncated":"McMaster University \/ Canadian Institutes of Health Research | McMaster Surgical Associates | Hamilton Health Sciences"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SOUTH KOREA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"YH14618","moa":"Wnt signalling pathway","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SOUTH KOREA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"YH14618","moa":"Wnt signalling pathway","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Osaka University","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Preclinical","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Osaka University","highestDevelopmentStatusID":"4","companyTruncated":"Astellas Pharma \/ Osaka University"},{"orgOrder":0,"company":"GCS Ramsay Sant\u00e9","sponsor":"Euraxi Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"GCS Ramsay Sant\u00e9","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GCS Ramsay Sant\u00e9 \/ Euraxi Pharma","highestDevelopmentStatusID":"11","companyTruncated":"GCS Ramsay Sant\u00e9 \/ Euraxi Pharma"},{"orgOrder":0,"company":"Royal College of Surgeons, Ireland","sponsor":"Health Service Executive, Ireland","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"IRELAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Royal College of Surgeons, Ireland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal College of Surgeons, Ireland \/ Health Service Executive, Ireland","highestDevelopmentStatusID":"1","companyTruncated":"Royal College of Surgeons, Ireland \/ Health Service Executive, Ireland"},{"orgOrder":0,"company":"Vertos Medical, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Vertos Medical, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vertos Medical, Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Vertos Medical, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"University of Miami","sponsor":"Arthrex","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Miami \/ Arthrex","highestDevelopmentStatusID":"10","companyTruncated":"University of Miami \/ Arthrex"},{"orgOrder":0,"company":"Henry Ford Health System","sponsor":"SMITH & NEPHEW INC","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Henry Ford Health System","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Henry Ford Health System \/ SMITH & NEPHEW INC","highestDevelopmentStatusID":"11","companyTruncated":"Henry Ford Health System \/ SMITH & NEPHEW INC"},{"orgOrder":0,"company":"TriHealth","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"TriHealth","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TriHealth \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TriHealth \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Solution","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Alpha Healthcare Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Merger","leadProduct":"Beta-tricalcium Phosphate","moa":"||Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Carmell Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0.14999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Carmell Therapeutics \/ Alpha Healthcare Acquisition Corp","highestDevelopmentStatusID":"8","companyTruncated":"Carmell Therapeutics \/ Alpha Healthcare Acquisition Corp"},{"orgOrder":0,"company":"Asterogene Biomedical Co. Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Autologous Nucleus Pulposus Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Asterogene Biomedical Co. Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Asterogene Biomedical Co. Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Asterogene Biomedical Co. Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Olayemi Osiyemi MD","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ceftaroline Fosamil","moa":"Bacterial penicillin-binding protein","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Olayemi Osiyemi MD","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Olayemi Osiyemi MD"},{"orgOrder":0,"company":"Roche Diagnostics GmbH","sponsor":"Lene Bergendal Solberg","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Zoledronic Acid","moa":"Farnesyl diphosphate synthase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Roche Diagnostics GmbH","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roche Diagnostics GmbH \/ Lene Bergendal Solberg","highestDevelopmentStatusID":"11","companyTruncated":"Roche Diagnostics GmbH \/ Lene Bergendal Solberg"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Valera Bussell","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Valera Bussell","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Valera Bussell"},{"orgOrder":0,"company":"Radius Health","sponsor":"Daniel Horwitz","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Abaloparatide","moa":"Parathyroid hormone receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Radius Health \/ Daniel Horwitz","highestDevelopmentStatusID":"11","companyTruncated":"Radius Health \/ Daniel Horwitz"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Shane Burch","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Teriparatide","moa":"Parathyroid hormone receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Shane Burch","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Shane Burch"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Jose Soberon","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacira BioSciences \/ Jose Soberon","highestDevelopmentStatusID":"11","companyTruncated":"Pacira BioSciences \/ Jose Soberon"},{"orgOrder":0,"company":"Bone Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Magnesium Oxide","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"IND Enabling","graph3":"Bone Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Bone Solutions \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Bone Solutions \/ Undisclosed"}]
Find Clinical Drug Pipelines for Orthopedics/Orthopedic Surgery
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
